ADVENTRX Pharmaceuticals to Be Listed on AMEX SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (ADVENTRX or "Company") (BULLETIN BOARD: AVRX) announced today that it has received approval from the American Stock Exchange (the "Exchange") to list its share of common stock in the Exchange under trading symbol "ANX." This approval is contingent upon ADVENTRX being in full compliance with all applicable listing standards on the date it begins trading on the Exchange. The Company expects to begin trading on the Exchange on April 29, 2004. "Listing on the Exchange is an important milestone and an initial step to gain greater visibility and recognition for the Company from the investment community," said Nicholas Jon Virca, ADVENTRX President and CEO. "We anticipate this to be one in a series of truly positive steps for the organization and our shareholders." ADVENTRX will be represented by the specialist firm of Cohen Specialists LLC on the Exchange trading floor. About ADVENTRX ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: The Ruth Group Investors: Stephanie Carrington 646-536-7017 Media: Cynthia Isaac, Ph.D. 646-536-7028 DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors - Stephanie Carrington, +1-646-536-7017, or Media - Cynthia Isaac, Ph.D., +1-646-536-7028, both of The Ruth Group, for ADVENTRX Pharmaceuticals, Inc.

Copyright